Found 7 matching trials
Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma
EARLY_PHASE1The investigators developed a dual-target CAR-T targeting CD38 and CS1. Pre...
Status
Active Not Recruiting
Location
Second Hospital of Shandong University
T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma
PHASE1This is a single-center, open-label, single-arm study to evaluate the safet...
Location
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
PHASE1This phase I trial studies the side effects and best dose of CS1-chimeric a...
Location
City of Hope Medical Center
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
PHASE1This is a Phase I, FIH, open-label, dose escalation study evaluating Safety...
Location
UCSF Medical Center- Helen Diller Family Comprehensive Cancer Center
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
PHASE1This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T...
Location
Dana-Farber Cancer Institute
A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
EARLY_PHASE1Clinical trial for the safety and efficacy of CS1-targeted CAR-T Cells ther...
Location
The First Affiliated Hospital,College of Medicine, Zhejiang University
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_PHASE1A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patie...
Location
The First Hospital of Zhejiang Medical Colleage Zhejiang University